Related Experiment Video
Updated: Jun 26, 2025

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions
David J Gagnon1,2,3, Melody J Glenn4,5, Aurora A Quaye3,6,7
1Department of Pharmacy, Maine Medical Center, Portland, ME, USA.
Abstract:
The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.
Related Concept Videos
Restorative Care
Drug Dependence
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management

